Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 19/20 | 0.89 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12979728 | 0.94 | GRM5 (1.00) | GRM5 | |
| SCHEMBL2011004 | 0.91 | GRM5 (0.87) | GRM5 | |
| SCHEMBL30794997 | 0.91 | GRM5 (0.87) | GRM5 | |
| SCHEMBL30794950 | 0.88 | GRM5 (0.82) | GRM5 | |
| SCHEMBL2014523 | 0.88 | GRM5 (0.82) | GRM5 | |
| SCHEMBL2015707 | 0.86 | GRM5 (1.00) | GRM5 | |
| SCHEMBL6893559 | 0.84 | GRM5 (0.70) | GRM5 | |
| SCHEMBL2014559 | 0.82 | GRM5 (0.89) | GRM5 | |
| SCHEMBL30795881 | 0.82 | GRM5 (0.89) | GRM5 | |
| SCHEMBL2012227 | 0.82 | GRM5 (0.90) | GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9040707-B2 | Bicyclic thiazoles as allosteric modulators of mGluR5 receptors | JANSSEN PHARMACEUTICA NV (BE) | 2015-05-26 | — | — | US | claimed |
| EP-2513117-B1 | BICYCLIC THIAZOLES AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2013-08-28 | — | — | EP | claimed |
| US-20120258955-A1 | BICYCLIC THIAZOLES AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2012-10-11 | — | — | US | claimed |
| EP-4584250-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | Biohaven Therapeutics Ltd. (VG) | 2025-07-16 | — | — | EP | disclosed |
| WO-2024054811-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| US-9040707-B2 | Bicyclic thiazoles as allosteric modulators of mGluR5 receptors | JANSSEN PHARMACEUTICA NV (BE) | 2015-05-26 | — | — | US | disclosed |
| EP-2513117-B1 | BICYCLIC THIAZOLES AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2013-08-28 | — | — | EP | disclosed |
| EP-2513117-A1 | BICYCLIC THIAZOLES AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | Janssen Pharmaceutica, N.V. (BE) | 2012-10-24 | — | — | EP | disclosed |
| US-20120258955-A1 | BICYCLIC THIAZOLES AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2012-10-11 | — | — | US | disclosed |
| WO-2011073339-A1 | BICYCLIC THIAZOLES AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120258955-A1 | BICYCLIC THIAZOLES AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | GRM5, GRIK5, GRM2 | GRM5 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.